Dermatologic adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.
Dermatologic adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.
Br J Dermatol. 2020 Apr 13;:
Authors: Pithadia DJ, Treichel AM, Jones AM, Julien-Williams P, Machado T, Moss J, Darling TN
Abstract
Systemic inhibitors of mechanistic target of rapamycin (mTOR) have antiproliferative, antiangiogenic, and immunosuppressive properties. In dermatology, they are effective for managing certain vascular anomalies and genodermatoses, notably tuberous sclerosis complex (TSC).1 Compared to cancer patients or transplant recipients, TSC patients are prescribed mTOR inhibitors at lower doses and their treatment regimens are less likely to include other drugs that may induce similar side effects.
PMID: 32282933 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Pithadia DJ, Treichel AM, Jones AM, Julien-Williams P, Machado T, Moss J, Darling TN Tags: Br J Dermatol Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Oral Cancer | Skin | Transplants | Tuberous Sclerosis | UK Health